Novartis agreed to buy an oncology-focused subsidiary from privately held Synnovation Therapeutics for up to $3 billion, the companies announced Friday.
Why it matters: The deal gives Novartis an early-stage breast cancer and solid tumor treatment, as the company contends with a steep patent cliff.
